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Purpose
Microsatellite instability (MSI) status may affect the efficacy of adjuvant chemotherapy in 
gastric cancer. In this study, the clinical characteristics of MSI-high (MSI-H) gastric cancer 
and the predictive value of MSI-H for adjuvant chemotherapy in large cohorts of gastric 
cancer patients were evaluated. 
Materials and Methods
This study consisted of two cohorts. Cohort 1 included gastric cancer patients who received 
curative resection with pathologic stage IB-IIIC. Cohort 2 included patients with MSI-H gas-
tric cancer who received curative resection with pathologic stage II/III. MSI was examined 
using two mononucleotide markers and three dinucleotide markers.   
Results
Of 359 patients (cohort 1), 41 patients (11.4%) had MSI-H. MSI-H tumors were more fre-
quently identified in older patients (p < 0.001), other histology than poorly cohesive, signet 
ring cell type (p=0.005), intestinal type (p=0.028), lower third tumor location (p=0.005), 
and absent perineural invasion (p=0.027). MSI-H status has a tendency of better disease-
free survival (DFS) and overall survival (OS) in multivariable analyses (hazard ratio [HR], 
0.4; p=0.059 and HR, 0.4; p=0.063, respectively). In the analysis of 162 MSI-H patients 
(cohort 2), adjuvant chemotherapy showed a significant benefit with respect to longer DFS 
and OS (p=0.047 and p=0.043, respectively). In multivariable analysis, adjuvant chemo-
therapy improved DFS (HR, 0.4; p=0.040). 
Conclusion
MSI-H gastric cancer had distinct clinicopathologic findings. Even in MSI-H gastric cancer 
of retrospective cohort, adjuvant chemotherapy could show a survival benefit, which was 
in contrast to previous prospective studies and should be investigated in a further prospec-
tive trial.
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Introduction
Microsatellite instability (MSI) is characterized as the increa- 
sed rate of uncorrected replication errors at the simple repeat 
sequence caused by a DNA mismatch repair gene (MMR) 
defect [1,2]. MSI-high (MSI-H) results in accelerated muta-
tions in oncogenes and tumor suppressor genes and a phe-
notype of hypermutational status [3,4]. Tumor-specific neo-
peptides may be generated during MSI-H carcinogenesis. 
A protective role of lymphocytes against MSI-H colorectal 
cancer that prevents tumor metastasis was reported [5]. 
Because of the immunologic aspect of MSI status, it was 
recently highlighted as a predictive marker in immunothera-
py. MSI-H tumors have been shown to benefit from immuno-
therapy, and anti–programmed death-1 antibody (pembroli-
zumab) has finally been approved by the U.S. Food and Drug 
Administration for the treatment of MSI-H tumors regardless 
of the tumor type [6,7]. 
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In an adjuvant setting, MSI-H could be a prognostic and 
predictive marker. In colorectal cancer, MSI-H tumor showed 
better prognosis than microsatellite stable (MSS)/MSI-low 
(MSI-L) tumors [8,9]. Patients with MSI-H colorectal cancer 
did not benefit from adjuvant chemotherapy. Particularly, 
adjuvant chemotherapy with 5-fluorouracil alone in patients 
with stage II colorectal cancer may be even worse than no 
adjuvant chemotherapy [8]. Therefore, adjuvant chemothera-
py with 5-fluorouracil alone in stage II colorectal cancer pati-
ents is not recommended by several guidelines [10,11].
In gastric cancer, adjuvant chemotherapy with capecitabine 
plus oxaliplatin or S1 has been proven to prolong survival 
after D2 resection of stage II/III gastric cancer in CLASSIC 
and ACTS-GC study [12,13]. MSI-H status is relatively com-
mon in gastric cancer and occurs in approximately 9% of sur-
gically resected gastric cancer [4,14-16]. In the CLASSIC trial, 
compared with the overall positive results, patients with MSI-
H gastric cancer did not experience any survival benefit from 
adjuvant chemotherapy [13,15]. Similarly, in the MAGIC trial, 
which evaluated the role of perioperative chemotherapy for 
resectable gastric cancer, MSI-H status had an improved prog-
nosis in the surgery-alone treatment arm, but a worse surviv-
al outcome in the chemotherapy-plus-surgery arm compared 
with an MSS/MSI-L [17,18]. A recently published paper of 
pooled individual patient data from four large randomized 
clinical trials conducted in patients with resectable gastric 
cancer (MAGIC [18], CLASSIC [13], ARTIST [19] which eval-
uated the concurrent irradiation with adjuvant chemotherapy 
[capecitabine plus cisplatin], and ITACA-S [20] which evalu-
ated an intensified combination chemotherapy schedule [fluo- 
rouracil plus leucovorin plus irinotecan followed by cisplatin 
plus docetaxel] compared with single-agent chemotherapy 
[fluorouracil plus leucovorin]) showed that patients with 
MSI-L/MSS gastric cancer benefited from chemotherapy plus 
surgery, but those with MSI-H gastric cancer did not [16]. 
However, in the CLASSIC and MAGIC trial, only 40 and 20 
patients had MSI-H tumors. In a pooled analysis of four 
clinical trials, 121 patients had MSI-H tumors, and just 33 
patients with MSI-H tumor who received surgery alone were 
included in the control group. Therefore, despite these results 
from randomized clinical trials and pooled analysis, there is 
limited statistical power for the use of MSI/MMR deficiency 
testing as a predictive marker for adjuvant chemotherapy in 
patients with curatively resected gastric cancer. 
Therefore, we evaluated the predictive value of MSI-H 
tumor for the benefit of adjuvant chemotherapy in large 
cohorts of gastric cancer patients. The clinical characteristics 




This study consisted of two cohorts. In cohort 1, the clini-
cal features of MSI-H compared with MSS/MSI-L were ana-
lyzed. Cohort 1 included gastric cancer patients who received 
curative resection with pathologic stage IB-IIIC from Febru-
ary 2005 to January 2006 at Seoul National University Hospi-
tal (SNUH). Cohort 2 was used for the analysis of the efficacy 
of adjuvant chemotherapy in MSI-H gastric cancer. Cohort 
2 included patients with MSI-H gastric cancer who received 
curative resection with pathologic stage II/III from January 
2007 to February 2012 at Seoul National University Bundang 
Hospital (SNUBH) and from December 2004 to June 2012 at 
SNUH. MSI-H patients in cohort 1 were included in cohort 
2. Clinical data were retrieved from the medical records of 
patients. The American Joint Committee on Cancer (AJCC) 
7th edition was used. 
2. Test for MSI 
Genomic DNA of the formalin-fixed gastric cancer tissues 
was extracted using standard proteinase-K digestion and a 
phenol/chloroform procedure. MSI was examined using two 
mononucleotide markers: BAT 25 (located 4q12-13 KIT gene, 
intron 16, T25 repeat) and BAT 26 (located 2p22-21, hMSH2 
gene, exon5, A26 repeat) and three dinucleotide markers: 
DS123 (located 2p 16.3, CA repeat), D5S346 (located 5q22.2, 
CA repeat), and D17S250 (located 17q12, CA repeat). Poly-
merase chain reaction (PCR) reactions were conducted in 
10 µL reaction volumes with fluorescent dye 50-end labeled 
primers. PCR products were denatured in formamide for 2 
minutes at 95°C and electrophoresed on denaturing 8% pol-
yacrylamide sequencing gels. MSI status was analyzed using 
GeneScan software in an ABI 3100 sequencer (Foster City, 
CA). Tissue samples that exhibited abnormal band patterns 
were considered to indicate MSI. According to the number 
of markers displaying instability of each tumor, the tumors 
were divided into MSI-H, MSI-L, and MSS. MSI-H indicated 
instability in two or more of five markers. MSI-L indicated 
instability in one of five markers. MSS indicated there was no 
instability in the five markers [1]. 
3. Statistical analysis
The differences in clinicopathologic findings according to 
MSI status were evaluated using chi-square analysis. Disease-
free survival (DFS) was defined as the duration between the 
surgical operation and disease relapse, any cause of death 
before disease relapse, or the last follow-up. The event for DFS 
was defined as relapse and any cause of death. Overall sur- 
vival (OS) was measured from the surgical operation to the 
last follow-up or any cause of death. The event for OS was 
defined as any cause of death. The Kaplan-Meier method was 
used for survival analysis with the log-rank test. The Cox 
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proportional hazards regression model was used to calculate 
hazard ratio (HR) in univariable and multivariable analysis. 
All statistical analyses were performed using SPSS Statistics 
ver. 25 (IBM Corp., Armonk, NY).
4. Ethical statement
This study was conducted in accordance with the ethical 
standards of the Declaration of Helsinki and the national and 
international guidelines. This study was approved by the 
institutional review board at SNUBH (B-1207-164-107) and 
Table 1.  Characteristics of gastric cancer patients with MSS/MSI-L and MSI-H (cohort 1)
Characteristic
 MSS/MSI-L  MSI-H 
p-value
 
 (n=318, 88.6%) (n=41, 11.4%)
Age (yr) 
    Median (range) 60 (28-87)  
    < 70 269 (92.4) 22 (7.6) < 0.001
    ≥ 70 49 (72.1) 19 (27.9) 
Sex   
    Male 214 (90.7) 22 (9.3) 0.083
    Female 104 (84.6) 19 (15.4) 
Operation   
    Total gastrectomy 109 (93.2) 8 (6.8) 0.066
    Subtotal gastrectomy 191 (85.3) 33 (14.7) 
    Partial gastrectomy 17 (100) 0 ( 
    Whipple 1 (100) 0 ( 
Histology   
    Tubular, well to poorly differentiated  253 (86.9) 38 (13.1) 0.045
    Poorly cohesive, signet ring cell type 42 (100) 0 ( 
    Other histological variants 23 (88.5) 3 (11.5) 
Laurena)   
    Diffuse 126 (92.0) 11 (8.0) 0.028
    Intestinal 147 (84.0) 28 (16.0) 
    Mixed 42 (95.5) 2 (4.5) 
Location   
    Upper third 21 (100) 0 ( 0.005
    Mid third 169 (92.3) 14 (7.7) 
    Lower third 128 (82.6) 27 (17.4) 
Stage   
    Ib 65 (85.5) 11 (14.5) 0.285
    IIA 71 (85.5) 12 (14.5) 
    IIB 56 (90.3) 6 (9.7) 
    IIIA 36 (83.7) 7 (16.3) 
    IIIB 58 (95.1) 3 (4.9) 
    IIIC 32 (94.1) 2 (5.9) 
Lymphatic   
    Absent 127 (92.7) 10 (7.3) 0.054
    Present 191 (86.0) 31 (14.0) 
Venous   
    Absent 271 (88.0) 37 (12.0) 0.386
    Present 47 (92.2) 4 (7.8) 
Perineural   
    Absent 136 (84.5) 25 (15.5) 0.027
    Present 182 (91.9) 16 (8.1) 
Adjuvant chemotherapy   
    Not applied 143 (78.1) 40 (21.9) 0.113
    Applied 149 (84.7) 27 (15.3) 
Values are presented as number (%) unless otherwise indicated. a)Unknown patients (n=3).
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SNUH (H-1208-100-422) and acquired a waiver of informed 
consent.
Results
1. Characteristics of patients with MSI-H gastric cancer 
compared with MSS/MSI-L gastric cancer (cohort 1) 
Cohort 1 was analyzed to evaluate the characteristics of 
MSI-H gastric cancer patients who received curative gastrec-
tomy. A total of 731 patients with gastric cancer received the 
curative operation with D2 dissection. Among these patients, 
366 patients with stage IA were excluded. MSI data were 
available in 359 of 365 patients with stages IB-IIIC. Cohort 
1 consisted of these 359 patients (Table 1). MSI-H status was 
seen in 41 patients (11.4%) and was associated with older age 
(27.9% vs. 7.6%, p < 0.001), other histology than poorly cohe-
sive, signet ring cell type (p=0.045), Lauren’s intestinal type 
(16% vs. 8.0% of disuse type, p=0.028), and lower third tumor 
location (17.4% vs. 7.7% of mid-third location, p=0.005). In 
contrast, there were no patients who had MSI-H tumors with 
poorly cohesive, signet ring cell type (0/42, 0.0%). There was 
no significant correlation according to stage (p=0.285), lym-
phatic invasion (p=0.054), or venous invasion (p=0.386), but 
MSI-H was identified more frequently in absent perineural 
invasion (p=0.027).
 
2. Survival of patients with MSI-H gastric cancer compared 
with MSS/MSI-L gastric cancer (cohort 1)
In cohort 1, the median follow-up duration was 71.1 months 
after surgery. Univariable analysis between clinicopathologic 
factors and survival was done (S1 Table). Patients with MSI-
H gastric cancer had better 5-year DFS rate (83.2% vs. 65.5%, 
respectively; p=0.070) (Fig. 1A), and 5-year OS rate (84.4% vs. 
71.7%, respectively; p=0.091) (Fig. 1B) than those with MSS/
MSI-L, although there was not significant. In the multivari-
able analysis with MSI status, sex, age, World Health Organi-
zation histology, Lauren classification, tumor location, lym-
phatic invasion, venous invasion, perineural invasion, and 
the use of adjuvant chemotherapy, MSI-H status showed an 
better survival although there was not statistical significance 
(for DFS: HR, 0.4; 95% confidence interval [CI], 0.2 to 1.0; 
p=0.059; for OS: HR, 0.4; 95% CI, 0.2 to 1.0; p=0.063) (Table 2).
In terms of the role of adjuvant chemotherapy in MSS/
MSI-L tumors, patients with adjuvant chemotherapy had 
the prolonged survival (for DFS: p=0.176 and p < 0.001; for 
OS: p=0.225 and p < 0.001 in stage II and stage III, respec-
tively). However, in MSI-H tumors, patients with adjuvant 
chemotherapy did not show the prolonged survival because 
of small sample size (for DFS: p=0.439 and p=0.836; for OS: 
p=0.439 and p=0.933 in 18 patients with stage II and 12 stage 
III, respectively).
3. Characteristics of MSI-H gastric cancer patients (cohort 2)
We next evaluated the efficacy of adjuvant chemotherapy 
in more MSI-H gastric cancer patients who received a cura- 
tive gastrectomy (cohort 2). In total, 5,983 patients were 
screened who received a gastrectomy and an MSI test. Of 
these 5,983 patients, 578 patients (9.7%) were confirmed as 
MSI-H. Finally, 162 patients who underwent R0 resection, 
were diagnosed with pathologic stage II/III, and were a can-
didate for adjuvant chemotherapy were included in cohort 
2 (S2 Fig.). The baseline characteristics of these patients are 
shown in Table 3. In this cohort, 38.9% of patients were over 
70 years old, and 58% were male. Tumor location of the lower 
third was observed in 62.3%. Intestinal type was found in 
52.5%. All patients had MSI-H gastric cancer, and 69.8% of 
patients showed instability in all five MSI markers. Patho-
logic stage II and stage III were identified in 77 (47.5%) and 
85 (52.5%), respectively. Lymph invasion, vascular invasion, 
and perivascular invasion were identified in 77.8%, 15.4%, 
and 37.7%, respectively. In addition, 75 patients (46.3%) were 
not treated with adjuvant chemotherapy. Fluoropyrimidine 
treatment alone, such as S1 or uracil and tegafur/leucovorin, 
Fig. 1.  Disease-free survival (A) and overall survival (B) according to microsatellite instability (MSI) status. p-value calculated by a Kaplan-
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was used in 42 patients (25.9%), whereas 40 patients (24.7%) 
were treated with fluoropyrimidine plus platinum, including 
5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin. 
There was no difference in the use of adjuvant chemothera-
py by stage, but the application of adjuvant chemotherapy 
decreased significantly with age (p=0.521 and p < 0.001). 
Of the patients who were ≥ 80 years old, 81.8% did not 
receive chemotherapy. In contrast, 82.4% of the patients 
under 60 years old were treated with adjuvant chemothera-
py, and 51.0% received combination therapy with fluoropy-
rimidine and platinum (p < 0.001) (S3 Table). 
4. Survival according to adjuvant chemotherapy in MSI-H 
gastric cancer patients (cohort 2)
In cohort 2, the median follow-up duration was 87.9 
months after surgery. Median DFS and OS of all patients 
Table 2.  Multivariable analysis for disease-free survival and overall survival (cohort 1)




 95%   
Hazard
 95%   
  
ratio
 Confidence p-valuea) 
ratio
 Confidence p-valuea)
   interval   interval
MSI 
    MSS or MSI-L  318 1   1  
    MSI-H  41 0.4 0.2-1.0 0.059 0.4 0.2-1.0 0.063
Sex       
    Male  291 1   1  
    Female  68 0.5 0.3-0.9 0.010 0.6 0.4-1.0 0.051
Age (yr)       
    < 70  236 1   1  
    ≥ 70  123 1.6 0.9-2.6 0.091 1.9 1.1-3.3 0.017
Histology       
    Poorly cohesive, signet ring cell type  42 1   1  
    Other  317 1.1 0.7-1.7 0.779 0.9 0.5-1.4 0.535
Lauren       
    Diffuse  137 1   1  
    Intestinal  175 0.7 0.4-1.1 0.114 0.7 0.4-1.1 0.129
    Mixed  44 1.0 0.5-1.8 0.943 1.0 0.5-1.8 0.939
Location       
    Upper third  21 1   1  
    Mid third  183 1.0 0.4-2.5 0.943 3.0 0.7-12.4 0.135
    Lower third  155 1.1 0.4-2.8 0.844 3.7 0.9-15.6 0.073
Stage       
    Ib  76 1   1  
    II  145 2.8 1.0-7.5 0.044 4.1 1.2-14.2 0.025
    III  138 14.0 5.2-38.2 < 0.001 20.0 5.8-69.6 < 0.001
Lymphatic       
    Absent  137 1   1  
    Present  222 2.1 1.2-3.6 0.010 1.8 1.0-3.2 0.048
Venous       
    Absent  308 1   1  
    Present  51 2.5 1.6-3.9 < 0.001 2.5 1.6-4.0 < 0.001
Perineural       
    Absent  161 1   1  
    Present  198 1.1 0.7-1.7 0.722 1.1 0.7-1.8 0.734
Adjuvant chemotherapy       
    Not applied  183 1   1  
    Applied  176 0.4 0.3-0.7 < 0.001 0.5 0.3-0.8 0.005
MSI, microsatellite instability; MSS, microsatellite stable; MSI-L, MSI-low; MSI-H, MSI-high. a)The Cox proportional hazards regression 
model was used.
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were not reached. The result of univariable analysis between 
clinicopathologic factors and survival was shown in S4 Table. 
MSI-H patients treated with adjuvant chemotherapy showed 
longer DFS and OS than patients without chemotherapy 
(p=0.047 and p=0.043, respectively) (Fig. 2A and B). In MSI-H 
patients with stage II, this benefit of adjuvant chemotherapy 
was observed (p=0.001 in DFS, p=0.001 in OS) but not in MSI-
H patients with stage III (p=0.867 in DFS, p=0.840 in OS). In 
patients who received fluoropyrimidine alone, the 5-year 
DFS and OS rates were 87.0% and 94.8%, respectively, which 
were higher than in the no adjuvant chemotherapy group 
(5-year DFS rate, 72.9%; p=0.044 [Bonferroni-corrected]; 
5-year OS rate, 78.3%; p=0.022 [Bonferroni-corrected]) (Fig. 
2C and D). In the fluoropyrimidine plus platinum group, the 
5-year DFS and OS rates were 72.4% and 89.5%, respectively, 
which were not significantly different from the no adjuvant 
chemotherapy (p=0.880 [Bonferroni-corrected] and p=0.956 
[Bonferroni-corrected], respectively). In addition, multivari-
able analysis with clinically significant factors, such as sex, 
age, stage, lymphatic invasion, venous invasion, perineural 
invasion, Lauren classification, and adjuvant chemotherapy, 
indicated that adjuvant chemotherapy in MSI-H gastric can-
cer patients was a significant independent prognostic factor 
for DFS (HR, 0.4; 95% CI, 0.2 to 1.0; p=0.040) (Table 4). 
Discussion
In this study, the clinical features and predictive role of 
MSI-H for adjuvant chemotherapy were evaluated in curati- 
vely resected gastric cancer. MSI-H gastric cancer had a ten-
dency of better prognosis than MSS/MSI-L after curative 
resection. In terms of the efficacy of adjuvant chemotherapy in 
MSI-H tumors, patients who received adjuvant chemothera-
py could experience longer survival than those without adju- 
vant chemotherapy. Particularly, even adjuvant chemothera-
py with fluoropyrimidine alone showed better survival than 
without adjuvant chemotherapy.
The clinical characteristics of MSI-H in curatively resect-
ed gastric cancer were distinctive from MSS/MSI-L. MSI-H 
tumor was diagnosed more frequently in older patients. In 
addition, MSI-H tumor was more common in patients with 
the intestinal type, other histology than poorly cohesive, sig-
net ring cell type, and lower third tumor location. These find-
ings were in accordance with previous studies [14,16]. In this 
study, MSI-H tumor was associated with present lymphatic 
invasion and absent perineural invasion. MSI was not cor-
related with early-stage cancers. This could be attributed to 
the exclusion of IA stage patients. In a previous study that 
included stage IA patients, MSI was observed more frequent-
ly in stage I (64.1%; T1, 44.1%; N0, 63.5%). Among stage II/III 
that were candidates for adjuvant chemotherapy, MSI-H was 
not observed frequently in earlier stage tumors [16].  
Table 3.  Characteristics of gastric cancer patients with MSI-H 
(cohort 2)
Characteristic No. (%) (n=162)
Age (yr)
    Median (range) 66.5 (37-95)
    ≤ 59 55 (34.0)
    60-69 44 (27.2)
    70-79 52 (32.1)
    ≥ 80 11 (6.8)
Sex 
    Male 94 (58.0)
    Female 68 (42.0)
Tumor location 
    Upper third 16 (9.9)
    Mid third 41 (25.3)
    Lower third 101 (62.3)
    Whole 4 (2.5)
WHO classification 
    Tubular, well differentiated 1 (0.6)
    Tubular, moderately differentiated 77 (47.5)
    Tubular, poorly differentiated 71 (43.8)
    Other histological variants 13 (8.0)
Lauren classification 
    Diffuse 50 (30.9)
    Intestinal  85 (52.5)
    Mixed 27 (16.7)
Instable microsatellite marker 
    2 18 (11.1)
    3 2 (1.2)
    4 29 (17.9)
    5 113 (69.8)
Pathologic stage 
    IIA 19 (11.7)
    IIB 58 (35.8)
    IIIA 43 (26.5)
    IIIB 27 (16.7)
    IIIC 15 (9.3)
Lymphatic invasion 
    Absent 36 (22.2)
    Present 126 (77.8)
Venous invasion 
    Absent 137 (84.6)
    Present 25 (15.4)
Perineural invasion 
    Absent 101 (62.3)
    Present 61 (37.7)
Adjuvant chemotherapy 
    No adjuvant therapy 75 (46.3)
    Fluoropyrimidine alone (S1, UFTE/LV)  42 (25.9)
    Fluoropyrimidine plus platinum (FP, XELOX) 40 (24.7)
    Unknown 5 (3.1)
MSI-H, microsatellite instability-high; WHO, World Health  
Organization; UFTE, uracil and tegafur; LV, leucovorin.
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MSI-H may be identified in just 7%-9% of resectable gas-
tric cancers [14,16]. In the early stage that is not a candidate 
for adjuvant chemotherapy, MSI-H might be more frequent-
ly identified. Therefore, evaluation of the efficacy of adju-
vant chemotherapy in MSI-H should be limited due to the 
small sample size. In previous studies related to the effects 
of adjuvant chemotherapy in MSI-H gastric cancer, only 40 
and 20 MSI-H patients from the CLASSIC and the MAGIC 
study were included [15,17]. Just 33 MSI-H patients who 
received surgery alone and 88 patients with MSI-H tumor 
who received preoperative or adjuvant chemotherapy were 
included in the pooled analysis of four randomized trials [16]. 
In a retrospective study of a large cohort of 1,990 patients, 
just 54 patients with stage II/III were included for analysis 
of 5-fluorouracil adjuvant chemotherapy [14]. These studies 
demonstrated that MSI-H tumors did not benefit from adju-
vant chemotherapy compared with MSS/MSI-L. However, 
due to small sample sizes, the use of these results to guide 
the application of adjuvant chemotherapy according to MSI 
status is limited. Although our study had a limitation due 
to its retrospective design, the population that was analyzed 
included 162 pathologic stage II/II patients with MSI-H 
tumor who were a candidate for adjuvant chemotherapy. 
This sample size was much larger than in previous studies. In 
contrast to previous studies, adjuvant chemotherapy could 
prolong the survival of patients, even in MSI-H gastric can-
cer. The efficacy of adjuvant chemotherapy in MSI-H patients 
could be an important clinical issue considering that MSI-H is 
more prevalent in older patients and those with an early stage 
of the disease. Therefore, this controversial result should be 
investigated in a further prospective study. Additionally, 
adjuvant chemotherapy with fluoropyrimidine alone sho- 
wed a benefit in terms of survival, but fluoropyrimidine 
and platinum combination did not show better survival as 
an adjuvant therapy significantly. There was not significant 
effect of adjuvant chemotherapy in stage III in which more 
fluoropyrimidine and platinum combination was applied. 
Based on these findings of our study, platinum could be 
assumed to have a detrimental effect in MSI-H gastric cancer. 
In most previous studies related with adjuvant therapy in 
MSI-H gastric cancer, fluoropyrimidine and platinum com-
bination was used. Fluoropyrimidine alone as an adjuvant 
chemotherapy in MIS-H gastric cancer was not evaluated. 
Therefore, adjuvant effect of fluoropyrimidine alone in MSI-
Fig. 2.  Survival according to adjuvant chemotherapy in microsatellite instability–high gastric cancer. Bonferroni-corrected p-values, calcu-
lated by a Kaplan-Meier method. (A) Disease-free survival according to adjuvant chemotherapy. (B) Overall survival according to adjuvant 
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H gastric cancer should be also evaluated in a further study.
In cases of MSI-H colorectal cancers, adjuvant chemo-
therapy with 5-fluorouracil alone may even have a detri-
mental effect on survival [8]. Therefore, recent guidelines do 
not recommend adjuvant chemotherapy with 5-fluorouracil 
alone in patients with MSI-H colorectal cancer [10,11]. How-
ever, it was reported that adding oxaliplatin could overcome 
this detrimental effect of 5-fluorouracil on patient survival 
in MSI-H colorectal cancers and that MSI-H alone did not 
affect survival in the case of adding oxaliplatin to treat stage 
III patients [21-24]. Inversely, in our study, adjuvant chem-
otherapy with fluoropyrimidine alone showed a benefit 
in terms of survival, which was different from the results 
obtained in colorectal cancer patients. It was reported that 
MSI status did not influence the survival of patients treat-
ed with 5-fluorouracil and the in vitro antitumor activity of 
5-fluorouracil in gastric cancer cells [25]. This difference bet- 
ween gastric cancer and colorectal cancer could be attribut-
ed to the biologic differences of MSI-H according to tumor 
type [26]. In our analysis for mutational profiles of MSI-H 
gastric and colorectal cancers from The Cancer Genome 
Atlas database, the mutational profile was different between 
gastric cancer and colon cancer (S5 Fig.). MSI-H colon cancer 
showed an increased rate of BRAF mutations compared with 
MSI-H gastric cancer (55% vs. 22%), but MSI-H gastric can-
cer exhibited more ARID1A, KMT2D, and RNF43 mutations 
than MSI-H colon cancer (S5 Fig.).
In conclusion, MSI-H tumor in patients with curatively 
resected gastric cancer had distinct characteristics with older 
age, intestinal type, other histology than poorly cohesive, 
signet ring cell type, lower third location, and absent peri-
neural invasion. MSI-H could be a better prognostic marker 
in curatively resected gastric cancer. In MSI-H gastric can-
cer, adjuvant chemotherapy could show a survival benefit, 
which was in contrast to previous prospective studies and 
should be investigated in a further prospective trial.
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Table 4.  Multivariable analysis for disease-free survival and overall survival (cohort 2)




 95%   
Hazard
 95%   
  
ratio
 Confidence p-valuea) 
ratio
 Confidence p-valuea)
   interval   interval
Sex 
    Male  94 1   1  
    Female  68 0.9 0.4-2.1 0.939 0.9 0.4-1.8 0.685
Age (yr)       
    < 70  99 1   1  
    ≥ 70  63 1.1 0.5-2.5 0.771 2.4 1.1-5.3 0.028
Lauren       
    Diffuse  50 1   1  
    Intestinal  85 0.7 0.3-1.5 0.319 0.7 0.3-1.6 0.443
    Mixed  27 0.4 0.1-1.5 0.166 0.3 0.1-1.2 0.076
Lymphatic invasion       
    Absent  36 1   1  
    Present  126 2.1 0.7-6.6 0.184 0.9 0.4-2.3 0.898
Venous invasion       
    Absent  137 1   1  
    Present  25 5.6 2.4-12.8 < 0.001 2.0 0.8-4.9 0.141
Perineural invasion       
    Absent  101 1   1  
    Present  61 1.0 0.5-2.1 0.948 1.0 0.5-2.1 0.960
Stage       
    II  77 1   1  
    III  85 2.1 0.9-4.9 0.077 1.3 0.6-2.7 0.553
Adjuvant chemotherapy       
    No adjuvant therapy  75 1   1  
    Adjuvant chemotherapy  82 0.4 0.2-1.0 0.040 0.7 0.3-1.5 0.327
a)The Cox proportional hazards regression model was used.
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